Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a report released on Friday. The firm set a "hold" rating on the medical research company's stock.

A number of other analysts have also recently commented on CTSO. D. Boral Capital restated a "buy" rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright restated a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $4.67.

Cytosorbents Trading Down 0.8 %

Shares of CTSO stock traded down $0.01 during trading hours on Friday, reaching $1.30. The company had a trading volume of 737,540 shares, compared to its average volume of 107,929. The company has a 50 day moving average of $0.99 and a 200 day moving average of $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market cap of $71.08 million, a price-to-earnings ratio of -3.61 and a beta of 0.61. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61.

Institutional Trading of Cytosorbents

A number of large investors have recently made changes to their positions in CTSO. Renaissance Technologies LLC increased its holdings in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after purchasing an additional 8,400 shares in the last quarter. Northern Trust Corp increased its holdings in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after purchasing an additional 16,701 shares in the last quarter. Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Millennium Management LLC bought a new position in Cytosorbents during the 4th quarter worth about $30,000. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.